Therapy News and Research

RSS

Accera to sponsor National Memory Screening Day of Alzheimer's Foundation of America

Accera, Inc., a privately-held, commercial-stage, healthcare company focused on the discovery and development of innovative clinical applications to address acute and chronic neurodegenerative diseases, announced today that it is a silver sponsor of the Alzheimer's Foundation of America's (AFA) National Memory Screening Day (NMSD) on November 13, 2012 during National Alzheimer's Disease Awareness Month.

27 Sep 2012

CeQur completes PaQ Insulin Delivery Device clinical study on type 2 diabetes

CeQur SA, a company focused on the development and commercialization of simple insulin delivery devices, announced the completion of a clinical study with the company's PaQ Insulin Delivery Device.

27 Sep 2012

Journal of Vascular and Interventional Radiology debuts new iPad app

As tablet ownership trends away from early adopters and moves to the mainstream, the Journal of Vascular and Interventional Radiology has debuted a new app, available for iPad users, that will allow readers to access interventional radiology literature and multimedia—when they choose, ensuring fast, convenient access to up-to-the-minute peer-reviewed articles, podcasts, images and more.

27 Sep 2012

Enrollment complete in Boehringer Ingelheim’s nintedanib phase III studies for IPF

Boehringer Ingelheim Pharmaceuticals, Inc. announced that clinical trial enrollment has completed for two phase III studies evaluating the safety and efficacy of nintedanib (BIBF 1120), an investigational compound, in patients with idiopathic pulmonary fibrosis (IPF), being studied at a twice-daily oral dose.

27 Sep 2012

CTCA at Midwestern named Certified Quality Breast Center of Excellence

Cancer Treatment Centers of America (CTCA) at Midwestern Regional Medical Center (Midwestern) has been recognized by the National Quality Measures for Breast Centers Program (NQMBC) as being among the top centers in the country for providing quality breast cancer care.

27 Sep 2012

Positive results from Sobi, Biogen Idec's rFIXFc Phase 3 trial on hemophilia B

Biogen Idec and Swedish Orphan Biovitrum (Sobi) today announced positive results from B-LONG, a clinical study that evaluated a new long-lasting clotting factor candidate in people with hemophilia B. Hemophilia B is a rare inherited disorder that impairs blood coagulation.

27 Sep 2012

Antibiotic therapy can effectively treat acute appendicitis

Although the standard approach to acute appendicitis is to remove the appendix, a study at the Sahlgrenska Academy, University of Gothenburg, Sweden, reveals that treatment with antibiotics can be just as effective in many cases.

27 Sep 2012

CSL develops new drug candidate against type 2 diabetes

CSL Limited has developed a new drug candidate that is able to prevent the development of type 2 diabetes and reverse its progression in animal models of the disease.

27 Sep 2012

Short-course amphotericin is cost-effective for cryptococcal meningitis

The treatment of cryptococcal meningitis in resource-limited settings is most effective with a short 1-week course of amphotericin induction therapy coupled with high-dose fluconazole for at least 2 weeks, a Ugandan study suggests.

26 Sep 2012

Tips on safe use of opioids in hospitals

On August 8, The Joint Commission issued a Sentinel Event Alert on the safe use of opioids in hospitals. The Alert discussed the significance of accurate pain assessment and effective pain management plans.

26 Sep 2012

NOXXON commences NOX-A12 Phase IIa trial in relapsed MM

NOXXON Pharma today announced the treatment of the first cohort of three multiple myeloma (MM) patients in a Phase IIa clinical trial of its anti-CXCL12/SDF-1 (CXC chemokine ligand 12 / Stromal Cell-Derived Factor-1) Spiegelmer NOX-A12.

26 Sep 2012

CivaTech Oncology receives NIH/NCI Phase II Contract for CivaSheet device to treat NSCLC

CivaTech Oncology, an RTP medical device company dedicated to developing novel radiation therapy devices, announced the award of a $1M Phase II Contract from the National Institutes of Health and the National Cancer Institute to further develop and commercialize CivaSheet, a bioabsorbable uni-directional device for treatment of non-small-cell lung cancer.

26 Sep 2012

Universitat de València to use optical technology to prevent myopia

The Universitat de València will use optical technology in order to prevent myopia, which is considered the most common eye disease in the world. Until now, this technology was only used in astronomy to study images of the Universe.

26 Sep 2012

Lifestyle changes can play a considerable role in influencing risk of cancer later in life

Lifestyle changes can play a considerable role in influencing the risk of developing cancer later in life. The key negative factors include smoking, lack of exercise and being overweight.

26 Sep 2012

PsiOxus initiates ColoAd1 phase I/II trial in metastatic solid tumours

PsiOxus Therapeutics, Ltd. has treated the first patient in its phase I/II clinical trial of ColoAd1for the treatment of metastatic solid tumours.

26 Sep 2012

HPV-positive oropharyngeal cancer patients have more rapid and robust radiation-therapy response

UC Davis cancer researchers have discovered significant differences in radiation-therapy response among patients with oropharyngeal cancer depending on whether they carry the human papillomavirus (HPV), a common sexually transmitted virus. The findings, published online today in The Laryngoscope Journal, could lead to more individualized radiation treatment regimens, which for many patients with HPV could be shorter and potentially less toxic.

26 Sep 2012

Regular mammography screening can help narrow racial gaps in breast cancer outcomes

Regular mammography screening can help narrow the breast cancer gap between black and white women, according to a retrospective study published in Breast Cancer Research and Treatment in August.

26 Sep 2012

UCSD evaluates safety and tolerability of dexanabinol in Phase I brain cancer study

Researchers at University of California, San Diego Moores Cancer Center are evaluating the safety and tolerability of a synthetic cannabinoid called dexanabinol (ETS2101). Delivered as a weekly intravenous infusion, the drug is being tested in patients with all forms of brain cancer, both primary and metastatic.

26 Sep 2012

New insights into filaminopathies

New insights into certain muscle diseases, the filaminopathies, are reported by an international research team led by Dr. Rudolf Andre Kley of the RUB's University Hospital Bergmannsheil in the journal Brain.

26 Sep 2012

Two tiny RNA molecules play a key role in pathological heart growth and failure

Cardiac stress, for example a heart attack or high blood pressure, frequently leads to pathological heart growth and subsequently to heart failure. Two tiny RNA molecules play a key role in this detrimental development in mice, as researchers at the Hannover Medical School and the Göttingen Max Planck Institute for Biophysical Chemistry have now discovered.

26 Sep 2012